Actively Recruiting
Personalized Oncogenomics (POG) Program of British Columbia
Led by British Columbia Cancer Agency · Updated on 2025-09-22
5000
Participants Needed
1
Research Sites
608 weeks
Total Duration
On this page
Sponsors
B
British Columbia Cancer Agency
Lead Sponsor
B
BC Cancer Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.
CONDITIONS
Official Title
Personalized Oncogenomics (POG) Program of British Columbia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.
- Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR have adequate archival tissue collected within 16 weeks of consent.
- Able to provide a blood test or other sample for germline genomic analysis.
- Have an ECOG performance status of 0 or 1.
- Be aged 18 years or older.
- Have an estimated life expectancy of at least 6 months and likely to be fit for a therapeutic clinical trial within 3-6 months.
- Have measurable disease according to RECIST v1.1 or updated criteria.
- Have adequate organ function.
- Understand that genomic data may guide treatment recommendations, including use or avoidance of therapies.
- Willing to share de-identified genomic and clinical data with research collaborators.
- Willing to be contacted for future studies based on their genomic data.
You will not qualify if you...
- Unable or unwilling to consent to tissue and blood sample requirements.
- Have a significant medical condition making participation unsuitable or unlikely to allow clinical trial eligibility within 12 weeks after biopsy.
- Unwilling or unable to provide treatment and outcome follow-up information.
- Unwilling to receive medically actionable genetic findings (germline or somatic).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
BC Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
Research Team
J
Janessa J Laskin, MD
CONTACT
M
Marco Marra, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here